Denice Torres - 03 Nov 2026 Form 4 Insider Report for Seaport Therapeutics, Inc. (SPTX)

Reporting relationship: Director
Issuer ticker: SPTX
Reported as of: 03 Nov 2026
Net transaction value: +$99,325
SEC form: 4
Accepted by SEC: 04 Nov 2026, 07:30:04 UTC
Prior SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Lana Gladstein, Attorney-in-Fact

Filing notes and source

Key filing fact

Denice Torres filed Form 4 for Seaport Therapeutics, Inc. (SPTX) on 04 Nov 2026.

Key facts

This page summarizes Denice Torres's Form 4 filing for Seaport Therapeutics, Inc. (SPTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 07:30.

Change

Previous filing in this sequence was filed on 29 Jun 2026.
Current net transaction value: +$99,325.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820278 Primary reporting owner

Torres Denice

Relationship: Director
Address: SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
Signature: /s/ Lana Gladstein, Attorney-in-Fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPTX transaction

Common Stock

Purchase

Transaction value: $99,325
Shares: +5,000
Change %
Price: $19.86
Shares after: 5,000
Date: 03 Nov 2026
Ownership: Direct

SPTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,406
Date: 03 Nov 2026
Ownership: By Denice M. Torres Revocable Trust
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.